Background TORCH infections during pregnancy significantly impact neonatal and maternal mortality rates worldwide. This study aimed to gather baseline serological data for pregnant women's immunological status to infection and determine if definite TORCH pathogens (cytomegalovirus, rubella virus, and Herpes simplex virus) were associated with Toxoplasma infection, to improve prenatal care and provide appropriate infection control strategies. Methodology Blood samples were gathered from 210 pregnant women attending Al Zagazig University hospitals from February to May 2023. Samples were examined for specific IgM and IgG antibodies against TORCH pathogens by electrochemiluminescence technique. Results Regarding TORCH infection, 60 (28.6%) cases were seronegative, while 77 (36.7%), 63 (30.0%), 56 (26.7%), and 15 (7.1%) were positive IgG antibodies against Toxoplasma gondii, cytomegalovirus, rubella virus, and Herpes simplex virus, respectively. There was no estimate for IgM for cytomegalovirus, rubella virus, or Herpes simplex virus, indicating that no primary infection had been detected during the pregnancy. There was a statistically significant association between seroprevalence of toxoplasmosis infections (IgM and IgG) and age group ≤ 25 years, which is the most common childbearing age group. Cytomegalovirus seropositivity was found in those beyond 25 years (P-value 0.001). Antibodies to mono-infections were found in 97/210 (46.2%) subjects. It is substantially higher under-25 years age group, 71/97 (73.2%), P-value of 0.001. 45/210 (21.4%) participants had antibodies to two agents, with no significant difference in the age group over 25 years, 26/45 (57.8%). Antibodies to three agents were assessed in eight instances, all under 25 years. Conclusions According to our findings, serological evaluation for the TORCH complex in all pregnant women is recommended to determine infection immunity, current immunization regimens, and infection reactivation. Low TORCH antibodies rates amongst pregnant women in Egypt's Sharqia governorate might be an appropriate starting point for prenatal screening initiatives.